Dr. Roland on the Rationale for a Neoadjuvant Checkpoint Blockade in Sarcoma

Video

Christina L. Roland, MD, PhD, discusses the rationale for a phase 2 study evaluating neoadjuvant checkpoint blockade study in patients with undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.

Christina L. Roland, MD, PhD, chief of Sarcoma Surgery; an assistant professor in the Department of Surgical Oncology in the Division of Surgery; and associate medical director of the Sarcoma Center at The University of Texas MD Anderson Cancer Center, discusses the rationale for a phase 2 study (NCT03307616) evaluating neoadjuvant checkpoint blockade study in patients with undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS).

In recent years, immunotherapy has started to emerge as a potential treatment modality in sarcoma, says Roland. At the 2019 ASCO Annual Meeting, results of the phase 2 SARC028 trial demonstrated objective responses with pembrolizumab (Keytruda) rates in both UPS and DDLPS.

In another phase 2 trial, nivolumab (Opdivo) was evaluated as a single-agent and in combination with ipilimumab (Yervoy) in the neoadjuvant setting. Notably, in this setting, patients typically have a lower burden of disease and are more likely to be cured.

The randomized phase 2 trial was modeled after a melanoma study, says Roland. The study was designed to assess the pathological response, a surrogate outcome for survival.

The results of the study showed significant clinical activity in patients with UPS who received nivolumab with or without ipilimumab plus concurrent radiation therapy, Roland concludes.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,